Intranasal capsaicin
Phase 3Small molecule
Intranasal capsaicin is one of 9 small molecule programs targeting Non-Allergic Rhinitis. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Non-Allergic Rhinitis
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Singulair
OOrganon and Co
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Xylocaine
MMEDRx USA, Inc.
Phase 3
SB-705498
GSKPhase 2
Intranasal capsaicin
TThe University of Texas Health Science Center, Houston
Phase 3
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Stapokibart
CChengdu Kangnuoxing Biopharma,Inc.
Preclinical
Oxymetazoline Hydrochloride
UUniversity of South Florida
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Biomarker1 trial
Pain Biomarker Study
Enrolling by invitation·TThe University of Texas Health Science Center, Houston·Phase 1·NCT03511846·371 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intranasal capsaicin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details